Inventor profile of:

Wayne Rothbaum

City:

Delray Beach, Florida

Country:

United States

Published Applications:

37

Last publication date:

2026-04-09

Top Assignees for applications by Wayne Rothbaum

The entities that hold a legal rights for patent applications filed by inventor Rothbaum Wayne:

Recent patent applications by Rothbaum Wayne

Wayne Rothbaum from Delray Beach, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-04-09
US20260097028A1
Human necessities

Methods of Treating Myeloproliferative Neoplasms

#2 | 2026-02-12
US20260041685A1
Human necessities

METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS

#3 | 2025-12-25
US20250387383A1
Human necessities

METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS

#4 | 2025-11-27
US20250360130A1
Human necessities

METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS

#5 | 2025-09-16
US18961657
Human necessities

Methods of treating indolent systemic mastocytosis

#6 | 2025-05-01
US20250134877A1
Human necessities

METHODS OF TREATING CANCER DEPENDENT ON MYC GENE EXPRESSSION

#7 | 2025-05-01
US20250134876A1
Human necessities

METHODS OF TREATING A CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS

#8 | 2025-03-20
US20250090517A1
Human necessities

Methods of Treating Cancer

#9 | 2024-07-04
US20240216380A1
Human necessities

BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment

#10 | 2024-06-20
US20240197742A1
Human necessities

Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor

#11 | 2022-12-08
US20220387434A1
Human necessities

COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT

#12 | 2022-03-24
US20220088013A1
Human necessities

Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor

#13 | 2022-02-24
US20220054472A1
Human necessities

Methods of treating myeloproliferative neoplasms

#14 | 2022-02-10
US20220040166A1
Human necessities

Methods and Compositions of Treating an Ophthalmic Condition

#15 | 2021-11-11
US20210346382A1
Human necessities

BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment

#16 | 2021-06-24
US20210186946A1
Human necessities

Methods of treating cancer

#17 | 2020-03-05
US20200069796A1
Human necessities

Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor

#18 | 2020-03-05
US20200069668A1
Human necessities

Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor

#19 | 2019-12-19
US20190381044A1
Human necessities

BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment

#20 | 2019-12-12
US20190374543A1
Human necessities

Therapeutic Combinations of an Antifolate and a BTK Inhibitor

#21 | 2019-12-12
US20190374539A1
Human necessities

Therapeutic combinations of a MEK inhibitor and a BTK inhibitor

#22 | 2019-07-11
US20190209591A1
Human necessities

Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor

#23 | 2019-01-24
US20190022092A1
Human necessities

Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist

#24 | 2019-01-10
US20190008869A1
Human necessities

Therapeutic Combinations of an Antifolate and a BTK Inhibitor

#25 | 2019-01-10
US20190008859A1
Human necessities

Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor

#26 | 2018-12-27
US20180369244A1
Human necessities

BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment

#27 | 2018-11-08
US20180317602A1
Human necessities

Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor

#28 | 2018-09-06
US20180250400A1
Human necessities

Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor

#29 | 2018-09-06
US20180250298A1
Human necessities

Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor

#30 | 2018-07-26
US20180207154A1
Human necessities

Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor

#31 | 2017-08-24
US20170239351A1
Human necessities

Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor

#32 | 2017-08-17
US20170231995A1
Human necessities

BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment

#33 | 2017-08-17
US20170231986A1
Human necessities

Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor

#34 | 2017-08-10
US20170224819A1
Human necessities

Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor

#35 | 2017-05-18
US20170136014A1
Human necessities

Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor

#36 | 2017-03-16
US20170071962A1
Human necessities

Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor

#37 | 2017-02-09
US20170035881A1
Human necessities

Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor

InventorID:

1790500 ⎘